Atux Iskay Group LLC
Plainsboro Township, NJ
- UEI
- C7JPQ5F3UUH7
- CAGE
- 88C46
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 6 Beechtree Ln, Plainsboro Township, NJ 08536, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $355,000 |
| FY2023 | $400,000 |
Contract awards
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Triterpenoid Therapeutics Inc. | Boston, MA | 813920 Professional Organizations |
| Seak Therapeutics, LLC | Memphis, TN | — |
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Stemsynergy Therapeutics Inc. | Miami, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
About the company
Atux Iskay Group LLC is a for-profit limited liability company registered to receive federal awards since January 14, 2019. The company specializes in developing innovative therapeutic technologies for the treatment of various diseases, with a focus on cancer and neurological disorders. Through federal contract and grant awards, Atux Iskay Group LLC primarily engages in research and development activities aimed at creating novel drug candidates and treatment approaches. The company's work spans from early-stage concept development to preclinical studies, leveraging its expertise in protein phosphatase 2A (PP2A) activation and other molecular pathways.
In terms of federal contracts, Atux Iskay Group LLC has secured awards from the National Cancer Institute, a part of the National Institutes of Health. These contracts, designated as Small Business Innovation Research (SBIR) Program Phase I actions, support the development of therapeutic technologies for pediatric and rare cancers. Specifically, the company is working on sulfonyl-urea and sulfonamide protein phosphatase 2A activators as potential treatments for MYCN amplified neuroblastoma. Another contract focuses on developing senotherapeutic agents for cancer treatment. These awards are structured as firm fixed price contracts and are designated as total small business set-asides, with work primarily performed in Plainsboro Township, New Jersey.
Atux Iskay Group LLC has also received several federal grant awards to support its research initiatives. The National Cancer Institute awarded the company a project grant to develop novel small molecule activators of PP2A as potential therapeutics for Group 3 medulloblastoma, a type of pediatric brain tumor. This work involves scale-up synthesis, evaluation of lead compounds, and preclinical studies. The National Institute on Aging has provided funding for the development of PP2A activators as novel Alzheimer's disease therapeutics, supporting activities from lead compound optimization to pilot toxicology and efficacy studies. Additionally, the Defense Health Agency awarded a project grant for investigating the pharmacological activation of PP2A as a treatment approach for pulmonary fibrosis. These grants demonstrate Atux Iskay Group LLC's diverse research portfolio in addressing various medical conditions through innovative therapeutic approaches.
SBA capabilities narrative
Small molecule medicinal chemistry and Organic Synthesis. Proprietary PP2A activator therapeutics. Reagents for PP2A assay development
Quick answers
Is Atux Iskay Group LLC registered in SAM.gov?
Yes. Atux Iskay Group LLC's SAM.gov registration is active through January 6, 2027.
What is Atux Iskay Group LLC's CAGE code?
Atux Iskay Group LLC's CAGE code is 88C46, and its Unique Entity ID (UEI) is C7JPQ5F3UUH7.
How much has Atux Iskay Group LLC received in federal contracts?
Federal contracts obligated $755,000 to Atux Iskay Group LLC in fiscal years 2023 through 2027.
What is Atux Iskay Group LLC's most recent federal award?
Atux Iskay Group LLC's most recent federal contract award is Sbir concept award - therapeutics - sulfonyl-urea and sulfonamide PP2A activators as mycn amplified neuroblastoma (NBL)… (75N91024C00009), from National Cancer Institute (NIH), on February 15, 2024.
On GovTribe
See Atux Iskay Group LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors